Presidents Update April 2019
Fighting the Opioid problem
While it may at times seem as though we at Auburn are very strict with regards to our sales of controlled
drugs, we feel as though we are simply acting responsibly. We do whatever we can to not only protect
our license, but we also go above and beyond to make sure that we’re doing everything possible to see
that we can to help combat the illegal opioid problem and save lives.
On October 24, 2018, President Trump signed a bill that we feel will accomplish more than the billions
of dollars spent has done. Effective immediately, the DEA was required to give distributors access
to anonymized information showing purchase history for all narcotics by pharmacy. We can now see how
many dosage units pharmacies use of any narcotic.
DEA regulations require distributors to both know their customers and develop a system to identify and
report suspicious orders. We believe that this will help our regulatory department make better, more
informed decisions when reviewing customer requests for controls which should make our job and yours
In November of 2018 the FDA issued Mylan Labs a Warning Letter that has created numerous product shortages
throughout the industry. Teva has now also received a Warning Letter at one of their large plants that
may also create supply issues for some of their products. We have been working hard to find alternate
sources for any of the affected products.
With Lannett out of the Levothyroxine market and Mylan having some supply issues, this is a great time
to check out our prices on the Sandoz product. We have most NDC’s in stock and the prices are significantly
less. Talk to your Auburn Account Manager for details.
We have a lot of new short dates in stock from Teva/Actavis, Amneal, Sun, Cipla, and others. Ask your
Account Manager for a current list and remember -- check GenericBid.com every week for some super low